1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Japan >
  5. Meiji Acquires ARCALIS

M&A Deal Summary

Meiji Acquires ARCALIS

On November 14, 2024, Meiji acquired life science company ARCALIS

Acquisition Highlights
  • This is Meiji’s 1st transaction in the Life Science sector.
  • This is Meiji’s 1st transaction in Japan.

M&A Deal Summary
Date 2024-11-14
Target ARCALIS
Sector Life Science
Buyer(s) Meiji
Deal Type Add-on Acquisition

Target

ARCALIS

Fukushima , Japan
ARCALIS is an mRNA vaccines and therapeutics contract development and manufacturing organization (“CDMO”), jointly established by Axcelead, Inc. and Arcturus Therapeutics, Inc. ARCALIS was formed in 2021 and is based in Fukushima, Japan.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Meiji

Tokyo , Japan
Category Company
Founded 1946
Sector Life Science
DESCRIPTION

Meiji is providing efficacious and high-quality pharmaceutical products including therapeutics and vaccines for infectious diseases, therapeutics for central nervous system diseases and generic drugs, to meet various medical needs. Meiji was founded in 1946 and is based in Tokyo, Japan.

DEAL STATS #
Overall 1 of 2
Sector: Life Science M&A 1 of 2
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Japan M&A 1 of 1
Year: 2024 M&A 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2025-12-04 Lyric Bio

San Francisco, California, United States

Lyric Bio manufactures donor-derived and protein-based therapeutics, with an initial focus on immunoglobulin production. By leveraging proprietary tissue engineering technologies, it aims to end chronic shortages, reduce costs, and improve global drug access for life-saving medicines. Lyric Bio is based in San Francisco, California.

Buy -
Mergr

Solution for

Product

Company

Legal